A Phase 2, Multicentre, Open-label, Single Arm Study to Evaluate the Effectiveness and Safety of Rezafungin (as Acetate) in the Treatment of Chronic Pulmonary Aspergillosis (CPA) in Patients with Limited Treatment Options
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Rezafungin (Primary)
- Indications Aspergillosis
- Focus Therapeutic Use
- Sponsors Mundipharma Research
- 03 Feb 2025 New trial record